5,5-dimethyl-3-(3-methyl-4-nitrophenyl)imidazolidine-2,4-dione | 1252643-19-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 5,5-dimethyl-3-(3-methyl-4-nitrophenyl)imidazolidine-2,4-dione
• CAS: 1252643-19-8
• 化学式: C₁₂H₁₃N₃O₄
• 分子量: 263.253
• InChiKey: OJIYIBZVLWRXAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  95.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-氟-2-硝基甲苯 、 5,5-二甲基海因 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.17h， 以25%的产率得到5,5-dimethyl-3-(3-methyl-4-nitrophenyl)imidazolidine-2,4-dione
  参考文献：
  名称：

  IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT

  摘要：

  本申请的主题是一种新型咪唑啉-2,4-二酮衍生物，其通式为(I)，其中R1、R2、R3和X为变量。这些产品具有抗增殖活性。它们特别适用于治疗与异常细胞增殖相关的病理条件和疾病，如癌症。该发明还涉及含有上述产品的药物组合物以及用于制备药物的使用。

  公开号：

  US20120095068A1

文献信息

• IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG
  申请人：Prevost Gregoire

  公开号：US20120083514A1

  公开（公告）日：2012-04-05

  The present application relates to novel imidazolidine-2,4-dione derivatives of the general formula (I), where R 1 , R 2 , R 3 , R 4 , X, and Y are variables. Said materials have an antiproliferative activity. They are particularly useful for treating pathological conditions and diseases, such as cancer, that are linked to abnormal cell proliferation. The invention also relates to pharmaceutical compositions containing said materials and to the use thereof for preparing a drug.

  本申请涉及一种新的咪唑啉二酮衍生物，其通式为（I），其中R1、R2、R3、R4、X和Y为变量。所述材料具有抗增殖活性。它们特别适用于治疗与异常细胞增殖相关的病理状况和疾病，如癌症。该发明还涉及含有所述材料的药物组合物，以及将其用于制备药物的用途。
• ANTIBODIES
  申请人：Sathyanarayanan Sriram

  公开号：US20120058112A1

  公开（公告）日：2012-03-08

  The combination of an IGF-1R antagonist such as a humanized antibody and an anti-proliferative drug is described. In a preferred embodiment, the present invention describes the combination of an IGF-1R antibody and an anti-proliferative drug belonging to the EGFR-inhibitor class, which is preferably erlotinib. The combination according to the present invention is useful for the treatment of tumours, including IGF-1R and/or EGFR mediated or dependent tumours.

  本发明描述了IGF-1R拮抗剂（例如人源化抗体）和抗增殖药物的组合。在一种优选实施方案中，本发明描述了IGF-1R抗体和属于EGFR抑制剂类的抗增殖药物（优选为厄洛替尼）的组合。根据本发明的组合对于治疗肿瘤，包括IGF-1R和/或EGFR介导或依赖的肿瘤是有用的。
• BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY
  申请人：Wang Yan

  公开号：US20110091524A1

  公开（公告）日：2011-04-21

  The present invention provides, for example, methods for conveniently determining if a cancerous condition in a subject will be responsive to an IGF1R inhibitor. The invention includes patient selection methods and methods of treatment.

  本发明提供了方便确定受试者的癌症状况是否对IGF1R抑制剂具有响应的方法。该发明包括患者选择方法和治疗方法。
• METHODS OF TREATMENT
  申请人：Wang Yan

  公开号：US20110262525A1

  公开（公告）日：2011-10-27

  This invention relates to compositions and methods useful for treating various cancers. Therapeutic combinations and methods of use thereof are also covered in the present application.

  本发明涉及用于治疗各种癌症的组合物和方法。本申请还涵盖了治疗组合物和使用方法。
• Imidazolidine-2,4-dione derivatives, and use thereof as a cancer drug
  申请人：Prevost Grégorie

  公开号：US08710091B2

  公开（公告）日：2014-04-29

  The present application relates to novel imidazolidine-2,4-dione derivatives of the general formula (I), where R1, R2, R3, R4, X, and Y are variables. Said materials have an antiproliferative activity. They are particularly useful for treating pathological conditions and diseases, such as cancer, that are linked to abnormal cell proliferation. The invention also relates to pharmaceutical compositions containing said materials and to the use thereof for preparing a drug.

  本申请涉及一种新型咪唑烷-2,4-二酮衍生物，其通式为(I)，其中R1、R2、R3、R4、X和Y均为变量。该物质具有抗增殖活性，特别适用于治疗与异常细胞增殖相关的病理情况和疾病，如癌症。本发明还涉及含有该物质的制药组合物以及其用于制备药物的用途。